Literature DB >> 9710117

AML1-like transcription factor induces serine elastase activity in ovine pulmonary artery smooth muscle cells.

D A Wigle1, K E Thompson, S Yablonsky, S H Zaidi, C Coulber, P L Jones, M Rabinovitch.   

Abstract

In previous studies, we showed that induction of pulmonary artery (PA) smooth muscle cell (SMC) elastase activity by serum-treated elastin (STE) requires DNA transcription. We therefore used differential mRNA display to identify transcripts expressed coincident with elastase induction. Twenty-four individual transcripts were differentially expressed from a screen of approximately 2000 mRNA sequences. An mRNA with sequence homology to the human transcription factor AML1 was identified and subsequently cloned from ovine PA SMCs. Since AML1 binds to a consensus sequence in the promoter of neutrophil elastase, we pursued the possibility that AML1 is a candidate transcription factor for SMC elastase. We documented by immunohistochemistry that serum stimulation induces increased expression of AML1 in the nucleus of PA SMCs. We also showed that STE induction of elastase activity is associated with early expression of AML1 mRNA and protein and that AML1 consensus sequence DNA binding activity is increased in nuclear extracts of STE-treated cells. In addition, AML1 antisense oligonucleotides reduced serum induction of elastase activity. Our study thus provides the first functional evidence of AML1 transcriptional activity related to elastase genes and offers novel insights into the broader biological significance of AML1 in nonmyeloid cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9710117     DOI: 10.1161/01.res.83.3.252

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  7 in total

1.  Expression profiles of elastase1 (NvElastaseI) and secretory leukocyte protease inhibitor (NvSLPI) during forelimb regeneration in adult Notophthalmus viridescens suggest a role in epithelial remodeling and delamination.

Authors:  Sandy Gian Vascotto; Shawn Beug; Richard A Liversage; Catherine Tsilfidis
Journal:  Dev Genes Evol       Date:  2006-03-01       Impact factor: 0.900

Review 2.  Molecular pathogenesis of pulmonary arterial hypertension.

Authors:  Marlene Rabinovitch
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

3.  Inhibiting lung elastase activity enables lung growth in mechanically ventilated newborn mice.

Authors:  Anne Hilgendorff; Kakoli Parai; Robert Ertsey; Noopur Jain; Edwin F Navarro; Joanna L Peterson; Rasa Tamosiuniene; Mark R Nicolls; Barry C Starcher; Marlene Rabinovitch; Richard D Bland
Journal:  Am J Respir Crit Care Med       Date:  2011-09-01       Impact factor: 21.405

4.  Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease.

Authors:  K N Cowan; P L Jones; M Rabinovitch
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

5.  Neutrophil elastase is produced by pulmonary artery smooth muscle cells and is linked to neointimal lesions.

Authors:  Yu-Mee Kim; Leila Haghighat; Edda Spiekerkoetter; Hirofumi Sawada; Cristina M Alvira; Lingli Wang; Swati Acharya; Gabriela Rodriguez-Colon; Andrew Orton; Mingming Zhao; Marlene Rabinovitch
Journal:  Am J Pathol       Date:  2011-07-19       Impact factor: 4.307

6.  Neonatal mice genetically modified to express the elastase inhibitor elafin are protected against the adverse effects of mechanical ventilation on lung growth.

Authors:  Anne Hilgendorff; Kakoli Parai; Robert Ertsey; G Juliana Rey-Parra; Bernard Thébaud; Rasa Tamosiuniene; Noopur Jain; Edwin F Navarro; Barry C Starcher; Mark R Nicolls; Marlene Rabinovitch; Richard D Bland
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-06-08       Impact factor: 5.464

7.  Suppressed smooth muscle proliferation and inflammatory cell invasion after arterial injury in elafin-overexpressing mice.

Authors:  S H Zaidi; X M You; S Ciura; S O'Blenes; M Husain; M Rabinovitch
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.